Inspire Medical Systems (INSP) Q4 2025: Coding Shift Drives 6% Revenue Range, Forcing Strategic Recalibration

2026-02-11 | By EarningsIQ Research

Reimbursement uncertainty around the Inspire 5 system forced Inspire Medical Systems to widen its 2026 revenue outlook, as the company navigates a transition to new coding and physician fee structures that directly impact procedure volume and profitability. Management is pursuing a dual-track approach: short-term mitigation of physician fee reductions and a long-term push for a new CPT code, while maintaining strong patient demand and operational discipline. Investors face a pivotal year as reimbursement clarity will dictate growth, physician adoption, and Inspire’s ability to sustain its innovation-driven momentum.

Summary

• Reimbursement Disruption: Coding transition for Inspire 5 introduces material physician fee risk and clouds volume visibility.
• Operational Flexibility: Strategic territory consolidation and cost controls support margin resilience amid top-line uncertainty.
• Guidance Hinges on Fee Clarity: 2026 growth depends on minimizing professional fee cuts and accelerating payer alignment.

Business Overview

Inspire Medical Systems develops and commercializes implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA), a chronic sleep disorder. The company’s primary revenue stream comes from sales of its Inspire Therapy systems (notably Inspire 4 and Inspire 5), which are distributed through a network of hospital and ambulatory surgery centers (ASCs) in the U.S. and selected international markets. Revenue is generated through product sales to medical centers and is highly dependent on reimbursement coverage and physician adoption. Key segments include the U.S. business (about 95% of revenue) and a small but growing international (OUS) presence (4-5%).

Performance Analysis

Inspire delivered double-digit revenue growth for both Q4 and the full year 2025, driven by increased utilization at existing centers and new center additions. Operating margin improved, benefiting from sales leverage and a higher mix of Inspire 5 procedures. Notably, the company generated positive operating income, robust cash flow, and executed $175 million in share repurchases over the year, ending with a strong cash position of $405 million.

However, the core narrative shifted sharply to reimbursement headwinds as the company transitions to CPT code 64582 with a Dash 52 modifier for Inspire 5 procedures. This change introduces a wide range of possible reductions to physician professional fees (10% to 50%), creating uncertainty for both procedure volumes and physician willingness to adopt the new system. Management’s widened 2026 revenue guidance (4% to 10% growth) directly reflects this risk, with the low end assuming the steepest fee cuts. The WISER prior authorization pilot in six states added further near-term disruption, particularly for Medicare cases.

• Margin Leverage From Product Mix: Higher Inspire 5 utilization drove gross margin gains, offsetting some operating expense growth.
• Cash Generation and Capital Return: Operating cash flow of $117 million and share repurchases signal confidence in long-term fundamentals.
• Territory Optimization: Intentional reduction in U.S. territories, with increased field clinical reps, improves resource allocation and supports center utilization.

While patient demand and clinical outcomes remain strong, reimbursement volatility is now the primary determinant of near-term trajectory.

Executive Commentary

Strategic Positioning

1. Coding and Reimbursement Navigation

The transition to CPT code 64582 with a Dash 52 modifier for Inspire 5 is the central strategic challenge. Management is working with Medicare Administrative Contractors (MACs, regional CMS intermediaries) and commercial payers to minimize the reduction in physician professional fees, arguing for a smaller cut based on the complexity and clinical benefit of Inspire 5. The uncertainty around the actual fee reduction (10% to 50%) is driving a cautious stance and broad guidance range.

2. Dual-Track Approach: Short-Term Mitigation and Long-Term Code Development

Inspire is pursuing a two-pronged strategy: Short-term, the company is focused on limiting the actual fee reduction and achieving national consistency, leveraging the 10,000 Inspire 5 procedures performed in 2025 as precedent. Long-term, management is committed to securing a new, dedicated CPT code for Inspire 5, with a realistic timeline for implementation by January 2028. This is seen as the only sustainable solution, as the Dash 52 modifier is not a permanent fix.

3. Operational Discipline and Resource Reallocation

Territory consolidation and a shift to more field clinical reps reflect a deliberate move to maximize efficiency and support center productivity. This operational recalibration is designed to maintain utilization even as some physician groups may pull back due to lower professional fees. Additionally, Inspire is optimizing its installed base by focusing on high-utilization centers and leveraging digital tools like SleepSync to streamline prior authorization and patient management.

4. Product Innovation and Pipeline Continuity

The company is not pausing R&D despite reimbursement headwinds. FDA approval for 3T MRI compatibility and ongoing development of Inspire 6 (with sleep detection and auto-activation) demonstrate a commitment to maintaining product leadership and clinical differentiation. These innovations are expected to further enhance adoption and adherence in the medium term.

Key Considerations

The 2026 outlook is defined by reimbursement risk, operational agility, and the durability of patient demand. Management’s guidance and commentary signal a year of transition, with significant upside or downside hinging on payer decisions and the pace of claims data accumulation.

Key Considerations:

• Physician Fee Sensitivity: The degree of professional fee reduction will directly impact procedure volumes, especially among private practice surgeons versus salaried academic centers.
• Patient Demand Remains Robust: Social media activity and direct-to-consumer marketing continue to drive a strong funnel, but bottlenecks may arise if physician willingness wanes.
• WISER Program Adds Near-Term Friction: Prior authorization requirements in six states are temporarily suppressing Medicare volumes, with improvement expected as technical issues are resolved.
• Inventory Flexibility: Sufficient Inspire 4 inventory allows some centers to opt for the legacy system, but the company expects most to remain with Inspire 5 given clinical advantages.
• Competition and GLP-1 Dynamics: Management built minor competitive impact into guidance and sees GLP-1 weight loss drugs as a net tailwind, potentially expanding the eligible patient pool.

Risks

Reimbursement volatility is the dominant risk, with the potential for larger-than-expected physician fee cuts undermining both volume and profitability. Prolonged payer uncertainty could dampen physician engagement and slow adoption, while the timeline for a new CPT code (not before 2028) extends the risk window. Execution risk around operational consolidation, competitive encroachment, and regulatory changes (WISER, RAC audits) add further complexity. Management’s broad guidance reflects these material uncertainties.

Forward Outlook

For Q1 2026, Inspire guided to:

• Revenue approximately flat year-over-year, reflecting coding disruption and WISER headwinds.
• Net loss expected due to lower revenue and higher operating expenses.

For full-year 2026, management widened guidance:

• Revenue range of $950 million to $1 billion (4% to 10% growth), with the low end assuming a 50% professional fee cut and the high end a 10% cut.
• Adjusted operating margin of 6% to 8%.
• Adjusted net income per diluted share of $1.85 to $2.35.

Management highlighted several factors that will drive results:

• Speed and magnitude of payer alignment on the Dash 52 modifier.
• Ability to sustain patient funnel and physician engagement amid reimbursement uncertainty.

Takeaways

Inspire’s 2026 performance will be determined by its ability to minimize physician fee reductions and maintain center productivity in a turbulent reimbursement environment.

• Guidance Range Reflects Fee Risk: Revenue and profit will swing based on where professional fee reductions settle, with management actively working to limit the downside.
• Operational Adjustments Cushion Impact: Territory consolidation, cost discipline, and patient demand investments support resilience even as headwinds mount.
• Payer Clarity Is the Next Catalyst: Investors should monitor MAC policy updates, claims data, and the pace of new CPT code development for directional signals.

Conclusion

Inspire Medical Systems enters 2026 at a strategic crossroads, with reimbursement risk overshadowing otherwise strong operational and product momentum. The company’s dual-track approach—short-term fee mitigation and long-term code creation—will define its ability to sustain growth and innovation in the face of material uncertainty.

Industry Read-Through

The reimbursement-driven volatility facing Inspire is a cautionary signal for the broader medtech sector, especially for companies reliant on physician fee-for-service models and new procedure codes. Coding transitions can rapidly reshape adoption curves, even for clinically superior products. The experience also highlights the importance of payer engagement, claims data, and diversified physician alignment (salary vs. private practice) in sustaining growth. Other device makers facing CPT code changes or prior authorization expansion should closely watch Inspire’s navigation of this environment, as payer pressure and operational agility increasingly define sector winners and losers.

INSP Healthcare Medical Devices Reimbursement Sleep Apnea Territory Management Innovation Coding Risk